Strategic Acquisition The company was acquired by Boston Scientific for 275 million in 2018, indicating a successful exit and potential enterprise sales opportunities through a larger parent organization with established channels in women's health.

Niche Focus Specializes in fallopian tube health assessment with the Mako 7 device and microcatheter technology, presenting a targeted opportunity to engage obstetrics/gynecology clinics, fertility centers, and pathology labs seeking innovative diagnostic tools.

Clinical Validation FDA 510(k) clearance achieved for Mako 7 in 2016, supporting regulatory credibility and a potential sales lane for clinical adoption, payer conversations, and reimbursement positioning.

Funding & Growth Raised venture funding totaling around 17 million prior to acquisition, suggesting a history of investor-backed growth and potential for continued partnerships with corporate buyers or license deals post-acquisition.

Market Positioning Small team (2-10 employees) within medical device manufacturing, implying highly targeted outreach through partner organizations and the parent company’s distribution networks to scale reach in women’s health diagnostics.